B+
Bull case
25%
Probability
Target price
$11.50
+105.4% vs current
ARDX
ArdelyxDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$8.00
+42.9% vs current
B-
Bear case
30%
Probability
Target price
$4.20
-25.0% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+80.3
Score
AI commentary
Deterministic signals lean positive, but only modestly: evidence quality (0.54) and uncertainty (0.563) support a cautious positive stance rather than an aggressive rerating call. The primary-source record is strongest around 2025 commercial results and 2026 guidance, while the peer set is loose and the forward pipeline hooks are real but not near-term enough to justify a high-conviction biotech upside memo.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystRDX10531 IND submission and first-in-human startHigh impact
Ardelyx said it is completing IND-enabling work for RDX10531 and plans an FDA IND submission in 2H 2026 with Phase 1 initiation thereafter, giving the company a second pipeline proof point beyond commercial tenapanor [#8-K-2026-02-19].
2026-12-31eventACCEL Phase 3 enrollment progress for CIC label expansionHigh impact
The 10-K says Ardelyx initiated the ACCEL Phase 3 CIC trial in January 2026, expects enrollment throughout 2026, and targets topline data in 2H 2027; clean execution through 2026 would support the view that IBSRELA can expand beyond IBS-C [#10-K-2026-02-19].
2026-12-31catalyst2026 product-revenue execution against raised commercial baseHigh impact
Management guided 2026 product revenue to $520-550M, including IBSRELA at $410-430M and XPHOZAH at $110-120M, after 2025 product revenue reached $377.8M; sustained quarterly delivery against that guide is the nearest driver, but XPHOZAH monetization remains a swing factor despite dispense growth [#8-K-2026-02-19].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology